Newsroom

neuroClues ISO27001:2022 certified for ISMS

Julien Tesse — Tue, 26 May 2026 13:52:14 GMT

Since April 3rd 2026 neuroClues is certified ISO27001:2022 for Information Security Management Systems by AFNOR. This certification is a strong recognition of our commitment to data security, reflecting our constant focus on protecting our partners and customers’ data by ensuring full compliance with the highest standards.

What is ISO/IEC 27001?

ISO/IEC 27001 is the most widely recognized global standard for Information Security Management Systems (ISMS) and sets out the requirements such a system must fulfill. It offers guidance for organizations of any size and across all industries on how to establish, implement, maintain, and continuously improve an ISMS.

ISO27001 is important because it provides a globally recognized framework to manage these risks in a consistent and auditable way. It helps organizations move from reactive security measures to a proactive and systematic approach. Being compliant with ISO27001 indicates that a company has implemented a structured approach to managing risks related to the security of the data it owns or handles, following internationally accepted best practices and principles.

To be certified, an independent external auditor verifies that the organization has implemented the required controls and follows them effectively. This gives assurance that security is not just a promise, but a structured and continuously monitored practice.

Eye Movements: A Key to Supporting Pharmaceutical Research - neuroClues

Julien Tesse — Tue, 26 May 2026 13:08:06 GMT

At RevArte in Edegem, clinicians are exploring how eye movements can reveal neurological disorders years before symptoms become visible.

Prof. Lafosse showcasing neuroClues® device

The rehabilitation hospital RevArte in Edegem (Belgium) was recently featured in Belgian media for its innovative use of neuroClues® eyetracking technology in neurological rehabilitation and cognitive assessment. In the article published by Het Nieuwsblad and Gazet van Antwerpen, Prof. Dr. Christophe Lafosse explains how subtle eye movement abnormalities may help identify brain disorders long before clinical symptoms appear.

“Hersenschuddingen, lichte beroertes en zelfs dementie”: according to the article, concussions, minor strokes, and even dementia can leave measurable signatures in eye movements years before patients notice functional impairments.

Looking at the Brain Through the Eyes

At RevArte, neuroClues® is being used to objectively quantify eye movements in patients presenting neurological or cognitive disorders. The technology captures high-frequency ocular data in only a few minutes through a portable and non-invasive CE-marked medical device.

The article highlights how eye tracking can support clinicians in detecting impairments linked to:

concussion and mild traumatic brain injury,
stroke-related neurological deficits,
neurodegenerative diseases such as dementia,
attention and visuospatial disorders.

For Prof. Dr. Christophe Lafosse and his team, the objective is not only earlier detection, but also a more precise and measurable follow-up of patients throughout rehabilitation.

A Natural Fit for RevArte’s Research-Driven Approach

The collaboration reflects RevArte’s longstanding expertise in neurorehabilitation and quantitative cognitive assessment. Prof. Dr. Christophe Lafosse has contributed extensively to research on visuospatial deficits, neurological rehabilitation, and cognitive disorders.

RevArte has also developed innovative assessment methodologies such as the RevArte Visual Search Task, designed to quantify visual attention and neglect in brain-injured patients.

Integrating neuroClues® into this clinical environment marks another step toward delivering more objective and quantitative insights into brain health.

Eye Movements as Early Neurological Biomarkers

Eye movements provide direct insight into brain function because they involve complex neural circuits related to cognition, motor control, attention, and executive functioning.

Today, almost 30,000 scientific publications link eye movements to neurological diseases, reinforcing the growing interest in eye tracking as a clinical biomarker. neuroClues® was developed to make these measurements accessible in routine clinical practice through a fast, easy-to-use platform for neurologists and rehabilitation specialists.

The media attention around RevArte’s work reflects the increasing momentum behind objective and quantified eye movement data and the role they may play in enabling earlier and more appropriate neurological care.

neuroClues crowdfunding on LITA: become a shareholder today.

Shirine Molaynejad — Wed, 06 May 2026 15:35:54 GMT

Brussels, 27 January 2026 — Today, we at P3lab (doing business as neuroClues) are launching our crowdfunding campaign on LITA. We’re inviting you to become a shareholder of a European MedTech with the ambition to revolutionize neurology

Who is neuroClues?

We are a MedTech company aiming to develop the stethoscope of the brain: a medical device that provides objective eye movement biomarkers. These biomarkers offer clinicians complementary information, helping to refine and objectify diagnosis and to improve the monitoring of neurological disorders.

Why does this matter?

1 in 3 people will develop a neurological disorder.

In Parkinson’s disease, for example:

The number of people affected is expected to double by 2040.
1 in 5 people diagnosed with Parkinson’s disease will receive a revised diagnosis within two years.
By the time patients receive their diagnosis, they have already lost up to 70% of their dopaminergic cells, limiting treatment effectiveness.

neuroClues is a class IIa medical device, CE marked under the (EU) Medical Device Regulation 2017/745, which we now aim to deploy across hospitals and clinics at the European level.

Why the eyes?

Your eyes are the window to your brain.

Decades of research have shown that oculomotor biomarkers reflect brain function and can provide powerful diagnostic insights.

Over 80,000 scientific articles on eye movements have been published in the past 60 years. This body of work clearly demonstrates the close connection between the central nervous system and eye movements.

Yet, despite their strong clinical potential, eye‑movement analysis remains largely underused in clinical practice, mainly because current eyetracking solutions are complex to implement and operate.

We want to change that.

Our Crowdfunding on LITA

For the first time, we’re opening our journey to everyone… not just professional investors. You can join us and help bring this technology into the hands of even more clinicians.

This campaign is part of the closing of our Serie A funding round.

What is LITA, and why this platform?

LITA.co is a European impact investment platform that allows everyday people to invest in companies that create positive social change.

We chose LITA because:

it supports mission-driven innovation,
it allows the public to become real shareholders,
and it fits perfectly with our vision of making neurological care more accessible

The neuroClues team brings together around 30 professionals with complementary expertise, distributed across the headquarters and manufacturing facility in Louvain-la-Neuve (Belgium), an office in Bordeaux, and an office in Paris within iPEPS at La Pitié-Salpêtrière (France’s first incubator dedicated to brain diseases). The team is supported by an experienced leadership, led by Antoine Pouppez, CEO, with 15 years of experience in the pharmaceutical and medical industries. Technology is overseen by Pierre Daye, CTO and research expert, while scientific expertise is provided by Pierre Pouget, Research Director at the Brain Institute (CNRS). Commercial strategy is driven by Bart Stulens, who brings over 25 years of experience in the pharmaceutical and medtech sectors, including at Medtronic.

Join the mission

You likely know someone affected by a neurological disorder : a parent, a friend, a colleague. Earlier and more accurate diagnosis allows for better patient care.

If you want to support European innovation in medical technology and help provide neurologists with the right tools to diagnose and monitor neurological disorders, contribute to advancing our ambition of becoming the “stethoscope of the brain” by joining the campaign on LITA.

Concussion Assessment and Monitoring with Eye Movement Biomarkers

Shirine Molaynejad — Sun, 16 Nov 2025 23:00:00 GMT

Clinical highlights – November 2025

neuroClues^® has officially received its CE-marking as a Class IIa medical device, available for clinical use in Europe.

We are excited to share insights into the potential of eye tracking. Every month, we keep you updated on the latest news shared by the scientific community.

In a previous edition, we explored how neuroClues^® biomarkers could provide insights into cognitive function [click here if you missed it]. This month, we turn our attention to concussion, highlighting how the biomarkers extracted with neuroClues^® may support assessment and monitoring in this context.

Enjoy the reading!

– The neuroClues^® Team

1. Concussion, the silent pandemic

Diagnosis of Concussion

Diagnosing concussions is complex: symptoms are often self-reported and may not appear immediately after the trauma.

Several factors contribute to missed or delayed diagnoses: concussions often lack visible signs, symptoms are subjective and variable, and they may overlap with other conditions such as migraines, anxiety, or depression. In some cases, symptoms appear only hours or days later, further complicating detection.

There are no single test used to diagnose concussions. Currently, diagnosis relies mainly on clinical judgment through medical history, neurological exams, cognitive testing, and balance assessments. CT or MRI scans are mainly used to rule out more serious injuries (such as bleeding and swelling), as concussions may not appear on imaging[6].

To avoid re-exposing vulnerable patients to further injury, sports physicians and associations have been seeking more objective ways to assess concussions.

1. Concussion Basics | HEADS UP | CDC

2. Concussions in Sports – American Brain Foundation

3. About Mild TBI and Concussion | Traumatic Brain Injury & Concussion | CDC

4. Concussion Resources & Facts | Concussion.org

5. https://biausa.org/brain-injury-fact-sheet

6. Diagnosing Concussion | NYU Langone Health

2. Relevance of Eye Tracking in Concussion

One promising avenue to address these diagnostic gaps lies in eye movement analysis.

Abnormalities in eye movements can be captured through biomarkers like latency and error rates, measured using tasks such as Visually Guided Saccades and Antisaccades. These biomarkers offer insight into specific neural pathway dysfunctions, making saccade assessment a powerful, non-invasive window into brain health.

→ We touched on this in a previous newsletter. Need a refresher? Click here to take another look.

The relationship between eye movements and mTBI has mainly been studied from a clinical perspective. In the literature review below, we selected publications showcasing the relevance of studying eye movements to quickly assess and follow up on traumatized patients in a quantified way.

Objective Measures of Visual Attention in TBI

Barone et al. (2023) investigated whether visual attention parameters measured through eye-tracking could help distinguish healthy individuals from patients with neurological disorders, including mild traumatic brain injury (mTBI) and different forms of epilepsy [7].

Using a simplified attention task combined with eye-tracking, the researchers analyzed how participants fixated, initiated saccades toward targets, and responded to stimuli [7].

The study revealed that several key metrics (such as fixation duration, saccade latency, visual reaction time, processing speed, and total reaction time) were able to differentiate patients with TBI from healthy controls. Patients with TBI in the study were categorised and assessed during two distinct periods: the acute phase (defined as ≤ 24 hours from injury) and the subacute phase (occurring 48 hours up to 3 months from injury) [7].

Importantly, the study did not include individual baseline measures prior to injury, which limits the ability to determine how much of the observed differences are due to the injury versus individual variability.

These findings are important because they highlight how eye movements and reaction times, which reflect underlying attention and processing efficiency, can serve as sensitive markers of neurological impairment. By capturing subtle differences, this type of assessment offers a promising tool for clinical evaluation and monitoring in TBI and other neurological disorders.

Eye-Tracking Metrics as Biomarkers in Concussion

A study by Feller et al. (2021) investigated which neuro-ophthalmologic measures could reliably distinguish athletes with recent concussions from healthy peers [8].

Using eye-tracking shortly after injury (median 19 days post-concussion), the researchers assessed 42 metrics across 11 types of visual tasks, including dynamic visual acuity, reaction time, smooth pursuits, and saccades [8].

The study found that reaction time and saccadic velocity were the most robust markers for differentiating concussed athletes from controls. Additionally, several metrics related to vertical saccades also showed discriminative potential [8].

However, the authors note that the study’s findings may not be applicable to older individuals or non-athletes. This limitation arises because athletes typically exhibit faster and more accurate eye movements than non-athletes, and these abilities tend to decline with age. Additionally, the study did not include individual baseline measurements, which further limits its generalizability.

Overall, the study highlights that targeted eye-tracking metrics can serve as objective biomarkers, supporting both diagnosis and clinical management of sports-related concussion.

Eye Movement Metrics and Recovery in Concussion

A study by Gallagher et al. (2020) explored eye movement performance in female athletes with concussion compared to healthy peers [9].

Using precise eye-tracking during pro- and anti-saccade tasks (looking toward or away from a visual target), the researchers identified measurable differences between the groups [9].

In the visually guided reflexive saccade task, concussed athletes showed reduced gain, slower peak velocity, and longer saccade duration, which were linked to a longer time to symptom recovery. In the anti-saccade task, a higher error rate helped distinguish concussed athletes from healthy controls [9].

These findings highlight that eye movement metrics can both detect concussion and predict recovery, offering a reliable, non-invasive tool to complement current symptom-based evaluations.

7. Barone V, Van Dijk JP, Debeij-van Hall MHJA, Van Putten MJAM. A Potential Multimodal Test for Clinical Assessment of Visual Attention in Neurological Disorders. Clin EEG Neurosci [Internet]. 2023 Sept [cited 2025 Feb 10];54(5):512–21. Available from: https://journals.sagepub.com/doi/full/10.1177/15500594221129962

8. Feller CN, Goldenberg M, Asselin PD, Merchant-Borna K, Abar B, Jones CMC, et al. Classification of Comprehensive Neuro-Ophthalmologic Measures of Postacute Concussion. JAMA Netw Open [Internet]. 2021 Mar 3 [cited 2025 Feb 17];4(3):e210599. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2776946

9. Gallagher V, Vesci B, Mjaanes J, Breiter H, Chen Y, Herrold A, et al. Eye movement performance and clinical outcomes among female athletes post-concussion. Brain Inj [Internet]. 2020 Oct 14 [cited 2025 Mar 3];34(12):1674–84. Available from: https://www.tandfonline.com/doi/full/10.1080/02699052.2020.1830173

3. Clinical Implications with neuroClues

The literature examples discussed above suggest that analyzing error rates and latencies from Visually Guided Saccades and Antisaccades can provide valuable insights into:

Differentiating concussed individuals from healthy controls using objective, quantifiable biomarkers
Predicting symptom severity and recovery trajectory following concussion
Assessing visual attention and processing speed deficits linked to neurological disorders

Leveraging neuroClues^® to extract these biomarkers could enhance concussion evaluation in clinical settings by offering reliable, efficient, and standardized measurements that could support diagnosis and personalized patient management.

Furthermore, the studies suggest the importance of including individual baseline measurements, as they can significantly strengthen the interpretation of results and improve the precision of clinical assessments.

Enjoyed this article?

Join our community to receive a monthly newsletter featuring insights on the relevance of eye tracking in the clinic and exclusive company updates

Instability of Neurological Diagnosis - neuroClues

Shirine Molaynejad — Tue, 15 Jul 2025 17:11:00 GMT

Clinical highlights – June 2025

neuroClues^® has officially received its CE-marking as a Class IIa medical device, available for clinical use in Europe.

To mark Brain Awareness Month, we’re taking a closer look at a critical challenge in neurological care: the stability and accuracy of diagnosis, particularly in conditions like Parkinson’s disease and dementia.

In this month’s newsletter, we explore the data behind diagnostic variability and why we believe biomarkers, including oculomotor ones, could be part of the way forward.

Enjoy the reading!

– The neuroClues^® Team

1. Parkinson's Disease Remains a Clinical Challenge

Getting an accurate diagnosis of Parkinson’s Disease (PD) remains a major challenge, impacting both patient care and research outcomes.

A recent Finnish study followed 1,626 people diagnosed with PD over 10 years, and the results highlight the considerable instability and clinical uncertainty associated with PD diagnoses [1]

Diagnosis Instability

The study revealed that 13.3% of initial Parkinson’s diagnoses were later revised, mostly within the first two years. When dementia with Lewy bodies (DLB) was counted separately from PD, the rate rose to 17.7% [1].

Many of the revised diagnoses turned out to be vascular parkinsonism, PSP, MSA, or clinically undetermined parkinsonism (CUPS). Other common culprits included essential tremor and drug-induced parkinsonism [1].

Why the revisions?

These findings reflect a broader challenge: early-stage symptoms often overlap, making it difficult to confidently diagnose PD in its early phases.

Limited role of “Gold Standard” methods

If we have “gold standards”, why do misdiagnoses persist?

The study shows that “gold standard” diagnostic methods aren’t widely used in routine practice. For example, DAT imaging was used in just 36% of patients mostly in cases with atypical symptoms or diagnostic uncertainty [1].

And while post-mortem neuropathology remains the definitive way to confirm PD, it was performed in only 3% of deceased patients [1]. This extremely low rate limits our ability to assess the true extent of misdiagnosis, as many possible misdiagnoses may never be identified.

PD diagnosis still relies heavily on clinical judgment, as physicians assess symptoms that often emerge gradually over time. This subjective approach leaves room for uncertainty and considerable variability between examiners. For instance, experienced neurologists may reach different diagnostic conclusions than general practitioners when evaluating the same patient.

Implications

The high rate of revised and uncertain diagnoses points to a major gap: we still lack accessible, objective and reliable tools to diagnose Parkinson’s accurately.

Even with updated clinical criteria and better imaging, diagnostic variability remains a problem. That’s why there’s growing need for robust, globally accessible diagnostic biomarker which could substantially improve diagnostic accuracy, particularly in areas with limited access to specialized neurologists or movement disorder experts.

1. Räty V, Kuusimäki T, Majuri J, Vahlberg T, Gardberg M, Noponen T, et al. Stability and Accuracy of a Diagnosis of Parkinson Disease Over 10 Years. Neurology [Internet]. 2025 May 13 [cited 2025 Jun 19];104(9):e213499. Available from: https://www.neurology.org/doi/10.1212/WNL.0000000000213499

2. Shift in Dementia Diagnosis in Routine Care

A study using German health claims data from over a decade (2004–2016) reveals that dementia subtypes like Alzheimer’s (AD), vascular dementia (VD), and others (oD) often change over time…and more than we might expect [2].

This study considered that the ICD-10 codes (codes used by physician to record diagnoses), as recorded by physicians in routine healthcare, directly represent the diagnoses.

Diagnosis Instability

The study found that a substantial number of changes occur in dementia diagnoses during the course of the disease, indicating that the initial etiological determination might not be conclusive shortly after the incident diagnosis [2].

Up to 46.1% of patients had their initial dementia diagnosis changed at least once within four years. Among those, diagnoses shifted between subtypes an average of 3 to 5 times [2].

Some Diagnoses Are Less Stable Than Others

Only 65.1% of Alzheimer’s patients kept the same diagnosis from start to finish.
For VD, this dropped to 53.9%, and for oD, it was 73.8%.
Patients initially diagnosed with AD had the highest number of changes and the fastest rate of change, with 30% receiving a new diagnosis within just 350 days [2].

Nature of the Diagnosis in Routine Care

While the precise clinical reasons for every diagnostic shift cannot be fully captured through health claims data alone, the study outlines several likely contributors to the observed changes in the recorded ICD-10 codes for dementia diagnoses:

Diagnoses are often provisional, as the underlying cause of dementia may not be clear at the time of the initial diagnosis and can change as the disease progresses.
Clinical judgment and context vary, meaning diagnoses often depend on the expertise of the individual clinician and the framework conditions under which care is delivered.
Subtype precision has limited practical impact, since differentiating between dementia types rarely affects treatment, prognosis, or billing, reducing the incentive to refine diagnoses [2]

Implications

Together, these factors illustrate that the lack of diagnostic stability is not just a matter of clinical variability, it reflects the absence of reliable, objective tools. Without standardized, accessible biomarkers, dementia diagnosis remains subjective and inconsistent.

Dementia diagnoses can change significantly over time. Therefore, researchers relying on routine healthcare data must interpret findings with caution, especially when studying specific subtypes like Alzheimer’s or vascular dementia. Categorising patients based on a single recorded diagnosis may oversimplify a more complex diagnostic journey.

2. Riedel O, Braitmaier M, Langner I. Stability of individual dementia diagnoses in routine care: Implications for epidemiological studies. Pharmacoepidemiol Drug Saf [Internet]. 2022 May [cited 2025 Jun 19];31(5):546–55. Available from: https://onlinelibrary.wiley.com/doi/10.1002/pds.5416

2. Need for Biomarkers

Accurately diagnosing Parkinson’s and dementia remains a challenge, especially in the early stages when symptoms overlap and current tools are limited in routine care.

Movement disorder specialists can identify subtle signs of parkinsonian syndromes, but in many regions, patients are managed by primary care physicians without access to this expertise.

Similarly, in the case of dementia, diagnoses often evolve over time and assessments may differ due to variations in clinical expertise and diagnostic frameworks.

This highlights the need for non-invasive, objective, low-cost and accessible biomarkers that can support diagnosis in everyday clinical settings.

At neuroClues, we see oculomotor biomarkers as a promising approach. Eye movements reflect brain function in a way that is measurable, accessible, and potentially valuable in improving diagnostic clarity.

We’re excited to see more research moving in this direction and to be part of the progress toward more accurate and accessible neurological care.

Enjoyed this article?

Join our community to receive a monthly newsletter featuring insights on the relevance of eye tracking in the clinic and exclusive company updates

Reliability of Oculomotor Biomarkers

Shirine Molaynejad — Tue, 24 Jun 2025 06:00:00 GMT

Clinical highlights – May 2025

neuroClues^® has officially received its CE-marking as a Class IIa medical device, available for clinical use in Europe.

For this occasion, we have decided to highlight how neuroClues^® can elevate your practice by focusing on the biomarkers it extracts and how proven research demonstrates their diagnostic value.

Previously, we’ve explored saccadic eye movements and their neural pathways, showing how abnormalities can offer valuable insights into brain health, particularly cognitive decline . In this blog, we take a closer look at the reliability of these oculomotor biomarkers and why that matters.

Enjoy the reading!

– The neuroClues^® Team

1. Reliability of Oculomotor Biomarkers

For a biomarker to be meaningful, it must be objective and consistent. Eye movement tasks, such as pro and anti-saccades, are increasingly recognized as sensitive indicators of brain function, with abnormalities linked to various neurological conditions.

To use these metrics in clinical or research settings, we first need to understand how they behave in healthy individuals: Are the values consistent within individuals over a period of time?

Knowing the normal range of variation allows us to determine whether a given result is truly atypical.

We have highlighted three key studies that address these questions. Together, they demonstrate that oculomotor parameters, measured with video-oculography, exhibit strong reliability within healthy populations, making them promising candidates for use as biomarkers.

Reliability over Time in Healthy Adults

Two large-scale studies have shown that oculomotor metrics (such as saccadic latency and error rate) can be measured with high precision and are remarkably consistent over time in healthy individuals. Let’s dive into them.

In this research, the team assessed the test–retest reliability of oculomotor tasks such as prosaccades and antisaccades. 21 participants (between 19 and 43 years old) were tested and then re-tested after after ~5 to 15 weeks to evaluate stability of oculomotor parameters and practice effects in healthy individuals.

The results were compelling:

🔹 Oculomotor performance remained stable over the period tested for most measures.
🔹 Antisaccade error rate, prosaccade latency, and antisaccade latency showed high test–retest reliability.
🔹 Within a single session, participants’ responses showed strong internal consistency.

These findings support the use of oculomotor tasks as reliable, non-invasive biomarkers. An important step in building their credibility in research and clinical settings [1].

1.Ettinger U, Kumari V, Crawford TJ, Davis RE, Sharma T, Corr PJ. Reliability of smooth pursuit, fixation, and saccadic eye movements. Psychophysiology [Internet]. 2003 Jul [cited 2025 Apr 15];40(4):620–8. Available from: https://onlinelibrary.wiley.com/doi/10.1111/1469-8986.00063

To evaluate the stability of these traits, a randomly selected subset participants (~10%) was retested after a median interval of 18.8 days. This allowed the researchers to determine how consistent individual performance was across sessions.

Their analysis revealed that multiple measures, including latencies and error rates, demonstrated high test-retest reliability over several weeks within individual.

The findings:

🔹 Underscore the potential of oculomotor metrics for future use as biomarkers or endophenotypes
🔹 Open the door for research into associations with other traits such as sex, cognitive style, or personality [2]

2.Bargary G, Bosten JM, Goodbourn PT, Lawrance-Owen AJ, Hogg RE, Mollon JD. Individual differences in human eye movements: An oculomotor signature? Vision Res [Internet]. 2017 Dec [cited 2021 Dec 15];141:157–69. Available from: https://www.sciencedirect.com/science/article/pii/S0042698917300391

Together, these findings reinforce the robustness of saccadic parameters when collected with a standardized approach, supporting their potential use in longitudinal research and their role as reliable physiological measures.

Reliability over Time within Age Groups

Płomecka et al. (2020) investigated the reliability of latency and error rates in saccadic eye movement tasks using an internationally standardized antisaccade protocol. Their study included a large sample of both young and older adults who were tested twice, one week apart, to evaluate age-related stability of oculomotor measures.

They found that:

🔹In older adults, both reaction time and error rate across pro- and antisaccade tasks demonstrated good to excellent reliability.

🔹In younger adults, antisaccade reaction time and error rate were also highly reliable.

🔹However, prosaccade error rate showed lower reliability in younger adults, likely due to the very low number of errors typically made on this simpler task

The study reported some of the highest reliability values to date for these metrics in saccadic tasks. It demonstrates that oculomotor measures (especially when derived from a standardized protocol) are stable over a period of one week in healthy individuals, including older adults, and can reliably capture individual differences.

This has important implications:

🔹 Measures were especially reliable in older adults, suggesting the protocol’s suitability for aging populations and longitudinal studies
🔹 Supports the potential use of these oculomotor metrics as biomarkers for cognitive decline
🔹 Reinforces the need for standardized methodologies when assessing neurocognitive function across the lifespan

These results provide further evidence that oculomotor tasks can produce highly consistent markers over time, reinforcing their potential as biomarkers for cognitive function and decline.

3.Płomecka MB, Barańczuk-Turska Z, Pfeiffer C, Langer N. Aging Effects and Test–Retest Reliability of Inhibitory Control for Saccadic Eye Movements. eneuro [Internet]. 2020 Sep [cited 2023 Nov 29];7(5):ENEURO.0459-19.2020. Available from: https://www.eneuro.org/lookup/doi/10.1523/ENEURO.0459-19.2020

2. Clinical Implications with neuroClues

The literature examples discussed above indicate that oculomotor biomarkers are indeed highly reliable, demonstrating consistency across time and tasks in different populations. This reliability is a foundational requirement for any metric intended for clinical use, supporting their relevance as objective, quantifiable measures of brain function.

That is why our ongoing discussions with Constances, the mega-cohort of 220,000 healthy participants, are instrumental: they will help establish a solid reference for the normal range of oculomotor performance with neuroClues.

We have built our technology around this scientific foundation. With neuroClues^®, these validated oculomotor biomarkers are now accessible in everyday clinical practice across Europe. Our CE marked device is designed to precisely capture these reliable metrics in a fast, reproducible, and standardized manner, providing a powerful and objective window into brain function.

Enjoyed this article?

Join our community to receive a monthly newsletter featuring insights on the relevance of eye tracking in the clinic and exclusive company updates

Exploring Anti-Saccades and Frontal Lobe Function - neuroClues

Shirine Molaynejad — Tue, 06 May 2025 09:00:00 GMT

Clinical highlights – April 2025

neuroClues has officially received its CE-marking as a Class IIa medical device, available for clinical use in Europe.

For this occasion, we have decided to highlight how neuroClues can elevate your practice by focusing on the biomarkers it extracts and how proven research demonstrates their diagnostic value.

In the previous blog, we explored saccadic eye movements and the neural structures involved. In this blog, we take it a step further by linking abnormalities in those movements to valuable insights into brain health, particularly cognitive impairments.

Enjoy the reading!

– The neuroClues^® Team

1. Quick recap

Saccades—rapid, precise eye movements—occur around 2.5 times per second and are regulated by distinct brain circuits.

Reflexive saccades are automatic responses, relying on lower-level pathways such as the brainstem and superior colliculus. In contrast, voluntary saccades are intentional and engage higher-order regions, including the prefrontal cortex (1).

1. Leng Q, Deng B, Ju Y. Application and progress of advanced eye movement examinations in cognitive impairment. Front Aging Neurosci [Internet]. 2024 Apr 17 [cited 2025 Feb 19];16. Available from:https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2024.1377406/full

Abnormalities in these eye movements can be captured through biomarkers like latency and error rates, measured using tasks such as Visually Guided Saccades and Antisaccades.

These biomarkers offer insight into specific neural pathway dysfunctions, making saccade assessment a powerful, non-invasive window into brain health.

→ We touched on this in last month’s newsletter. Need a refresher? Click here to take another look.

2. Link to Cognitive Impairment

Several recent studies suggest that measuring saccadic eye movements biomarkers may serve as valuable clinical tools for assessing cognitive impairments.

In this section, we will explore four of these studies in greater detail.

Behavioral Variant Frontotemporal Dementia (bvFTD)

Saccadic testing can offer valuable insights into frontal lobe dysfunction in bvFTD patients. A study found that, compared to healthy controls, bvFTD patients tend to show a general slowing in the initiation of eye movements, with increased latency due to motor pathway issues or delays in saccadic commands from higher cortical areas (2).

Voluntary saccades, such as antisaccades, displayed relatively more specific impairments, including a higher error rate, which may suggest poor inhibitory control and the reliance on frontal lobe function (2).

2. Douglass A, Walterfang M, Velakoulis D, Abel L. Behavioral Variant Frontotemporal Dementia Performance on a Range of Saccadic Tasks. Savage S, editor. JAD [Internet]. 2018 Aug 7 [cited 2025 Feb 27];65(1):231–42. Available from: https://journals.sagepub.com/doi/full/10.3233/JAD-170797

Mild Cognitive Impairment & Dementia

Anti-saccade tasks, both horizontal and vertical, were showned in this study to outperform horizontal pro-saccades in distinguishing between mild cognitive impairment (MCI) and dementia, with stronger associations to neuropsychological test results (3).

While vertical pro-saccades show promise, the study also highlights that anti-saccades, with their more consistent reaction times and high accuracy in clustering, may serve as sensitive markers of cognitive decline (3).

As illustrated in the figure above, reaction times (latencies) in visual saccade tasks, particularly vertical and anti-saccade, appear to effectively differentiate healthy older adults, individuals with MCI, and those with dementia, with notable distinctions observed between groups.

3. Rane D, Dash DP, Dutt A, Dutta A, Das A, Lahiri U. Distinctive visual tasks for characterizing mild cognitive impairment and dementia using oculomotor behavior. Front Aging Neurosci [Internet]. 2023 Jul 20 [cited 2025 Mar 12];15:1125651. Available from: https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2023.1125651/full

Amnestic (aMCI) & Non-Amnestic (naMCI) Cognitive Impairment

Saccadic eye movements have been found to help differentiate between subtypes of mild cognitive impairment (MCI) and healthy controls (HCs), with distinct variations in eye movement metrics being associated with specific cognitive functions (4).

This study demonstrated that individuals with aMCI tend to exhibit longer saccadic reaction times (SRTs), in other words latency, and a higher proportion of express saccades during anti-saccade tasks, which may reflect impairments in inhibitory control (4).

These saccadic abnormalities were linked to executive function and attention deficits, suggesting that they could serve as a valuable tool for identifying cognitive decline in the early stages of dementia (4).

4. Koçoğlu K, Hodgson TL, Eraslan Boz H, Akdal G. Deficits in saccadic eye movements differ between subtypes of patients with mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology [Internet]. 2021 Feb 7 [cited 2025 Feb 27];43(2):187–98. Available from: https://pubmed.ncbi.nlm.nih.gov/33792489/

Amnestic (aMCI) Cognitive Impairment & Alzheimer’s Disease

Objective saccadic eye movement tasks have been shows to effectively assess executive function deficits in individuals with amnestic mild cognitive impairment (aMCI) and mild Alzheimer’s disease (AD) (5).

Findings from this study suggest that both patient groups exhibit slower initiation of correct antisaccades and make more direction errors compared to healthy controls, highlighting impairments in inhibitory control and voluntary saccade generation (5).

The authors found a correlation between antisaccade performance and neuropsychological tests, such as the Stroop task, which further underscores the task’s sensitivity in detecting early cognitive decline. This suggests that evaluating antisaccade performance would be a valuable tool for assessing executive dysfunction in a non-invasive manner (5).

5. Peltsch A, Hemraj A, Garcia A, Munoz DP. Saccade deficits in amnestic mild cognitive impairment resemble mild Alzheimer’s disease. Eur J of Neuroscience [Internet]. 2014 Jun [cited 2025 Feb 7];39(11):2000–13. Available from:https://pubmed.ncbi.nlm.nih.gov/24890471/

3. Clinical Implications with neuroClues

The literature examples discussed above indicate that analyzing error rates and latencies from Visually Guided Saccades and Antisaccades may offer valuable insights into:

distinguishing subtypes of Mild Cognitive Impairment (MCI),
estimating the likelihood of clinical progression in amnestic MCI (aMCI) and assessing the risk of conversion to Alzheimer’s disease, potentially enabling earlier intervention,
detecting subtle deficits in executive function.

Therefore, leveraging neuroClues^® to automatically extract error rates and latency data from Visually Guided Saccades and Antisaccades could support the evaluation of cognitive impairments in a clinical setting.

Enjoyed this article?

Join our community to receive a monthly newsletter featuring insights on the relevance of eye tracking in the clinic and exclusive company updates

Neural Pathways of Voluntary and Reflexive Saccades - neuroClues

Shirine Molaynejad — Tue, 15 Apr 2025 08:15:00 GMT

Clinical highlights – March 2025

In this article, we explore the differences between voluntary and reflexive saccades, the neural pathway involved, and how they can provide interesting clues about brain health.

Now officially CE-marked as a Class IIa medical device, neuroClues® is available for clinical use across Europe. To mark this milestone, we’ll be highlighting in the coming months how neuroClues® can enhance your practice by focusing on the biomarkers it captures and the scientific research that supports their diagnostic value.

Enjoy the reading!

– The neuroClues^® Team

1. EYE MOVEMENTS

Throughout our lives, we trigger an astonishing 2.5 saccades per second, a frequency even higher than our heartbeats. Saccades are among the fastest movements the human body can perform.

Our eye movements are stereotypical, as we all move our eyes in similar patterns. This is advantageous because it makes any abnormalities highly noticeable.

Since different brain regions control these eye movements, abnormalities in eye behavior often point to specific areas of the brain that may not be functioning properly. This connection is why research has linked eye movement abnormalities to malfunctions in particular brain regions.

Klein & Ettinger (2019)

Eye Movement Assessment

To assess these movements, we rely on paradigms, a structured sequence of visual stimuli that prompts specific eye behaviors. These paradigms are vital for evaluating how the eyes respond to various targets, typically presented on a screen. Common examples of paradigms include visually guided saccades (also known as pro-saccades), anti-saccades, and others—see figure below.

Each paradigm follows a defined set of parameters, such as the position and timing of the visual target, collectively forming a protocol.

Within these protocols, we extract biomarkers. Examples include latency—the time between the appearance of a target and the initiation of a saccade—and error rate, which measures the frequency of incorrect eye movements. These biomarkers offer objective insights into eye behavior, allowing us to analyze multiple aspects of eye movement with precision.

Leng et al. (2024)

2. Saccades and Neural Pathway

Eye movements are classified based on their neural pathways into two types: low-level reflexive movements and high-level voluntary movements.

Leng et al. (2024)

Reflexive Eye Movements

Reflexive saccades are rapid, automatic eye movements directed toward a visual stimulus that suddenly appears in the peripheral field.

Neural Pathway

Reflexive saccades require minimal cognitive effort and are primarily controlled by neural circuits in the brainstem, with the superior colliculus in the midbrain playing a central role. The superior colliculus processes sensory information (such as location, size, shape, or brightness) to determine the saccade target and ensure accuracy in direction and endpoint. This exogenous information, linked to attentional processes, guides the initiation of reflexive saccades.

Paradigm

To study reflexive eye movements, Visually Guided Saccades (VGS) are used. In this task, the patient is asked to perform a saccadic eye movement toward a visual target (pro-saccades).

Additionally, the anti-saccade task is another method to study reflexive eye movements, as it relies on the ability to suppress reflexive saccades.

Link to Publication

Voluntary Eye Movements

Voluntary saccades are intentional eye rotations that require more complex processes than simple reflexive responses.

Neural pathway

Voluntary saccades engage various cortical areas, including pathways through the frontal lobe, to control eye movements. Unlike reflexive saccades, which primarily rely on a quick loop between the parietal cortex and the superior colliculus, voluntary movements require active input from frontal cortical regions^[Link]

Different tasks have been shown to involve specific brain areas:

Pro-saccades engage regions like the prefrontal cortex (PFC), frontal eye field (FEF), supplementary eye field (SEF), and parietal eye field (PEF).
Antisaccades involve the FEF, SEF, dorsolateral prefrontal cortex (DLPFC), PEF, and anterior cingulate cortex (ACC). Damage to the DLPFC and cingulate eye fields (CEF) increases errors, while FEF damage increases latency.
Memory-guided saccades are linked to the FEF, SEF, and PEF, which are crucial for spatial working memory. Extraretinal signals, such as vestibular input, also contribute.
Predictive saccades involve the FEF, SEF, DLPFC, and cerebellum.
Gap and overlap saccades mainly engage the FEF, PEF, and superior colliculus (SC), which are associated with visual attention shifts.

Paradigm

To study voluntary eye movements, several tasks can be used:

Visually Guided Saccades (VGS) (overlap)
Anti-saccades (AS)
Delayed saccades (DS)
Self-Generated Saccades (SGS)
Memory-Guided Saccades (MGS)
Predictive Saccades
Adaptive Saccades

Link to Publication

In essence, reflexive saccades are more stimulus-driven and involve lower-level motor pathways, whereas voluntary saccades are goal-directed, often require the suppression of reflexive responses, involve higher-level cognitive functions like executive control, working memory, and learning, and depend more heavily on cortical input, particularly from the frontal lobe.

3. neuroClues Technology

neuroClues offers a comprehensive tool for evaluating both voluntary and reflexive saccades, including Visually Guided Saccades and Antisaccades, allowing for the extraction of key biomarkers such as errors and latency.

As we highlight in this month’s review, these biomarkers can provide information about potential brain structure impairments.

For example, increased pro-saccade latency can indicate impairment in the PFC, FEF, SEF and PEF. On the other hand, increased anti-saccade latency could be indicative of damage in the FEF and increased anti-saccade error rates have been associated with damage to the DLPFC and CEF.

Stay tuned for next month, where we’ll dive into studies demonstrating the link between eye movement abnormalities and cognitive impairments.

Enjoyed this article?

Join our community to receive a monthly newsletter featuring insights on the relevance of eye tracking in the clinic and exclusive company updates

Oculomotor Biomarkers Recorded on 50 Patients with neuroClues®, now CE-Marked!

Shirine Molaynejad — Tue, 04 Mar 2025 08:45:00 GMT

Clinical highlights – February 2025

This month’s newsletter is eye-opening.

As you may know, neuroClues^® has officially received its CE-marking as a Class IIa medical device! And as if that wasn’t exciting enough, we’ve also reached a major milestone—50 patients recorded in the ICEBERG cohort. We’ll take a moment to explain what that means for us… and you!

As always, we’re committed to bringing you the latest insights on the power of eye tracking. This time, we’re presenting a fascinating review by Leng et al. (2024), which demonstrates how eye movement analysis is proving to be a promising tool for detecting cognitive impairment.

In the coming months, we’ll explore how neuroClues^® can elevate your practice by focusing on the biomarkers it extracts and how proven research demonstrates their diagnostic value. Stay tuned!

Enjoy the reading!

– The neuroClues^® Team

1. ICEBERG COHORT

The ICEBERG study, officially titled “Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson’s Disease,” is a comprehensive, ongoing longitudinal study focused on understanding Parkinson’s Disease (PD).With an aim to enroll 360 patients, this four-year natural history study aims to identify clinical, imaging, and biological markers of PD onset and progression for use in clinical trials of disease-modifying therapies.

Launched in November 2014 at Hôpital Pitié-Salpêtrière in Paris, ICEBERG is expected to reach its primary completion in November 2029. With neuroClues^® now part of the study, 50 patients have already been successfully recorded!

The Parkinson’s Iceberg

Parkinson’s Disease (PD) has been compared to an iceberg, where the visible symptoms—such as tremors, rigidity, and slow movements—are just the tip. Beneath the surface lie a host of hidden, non-motor symptoms from sleep disturbance to cognitive impairment.

The clinical symptoms of Parkinson’s Disease are just the visible result of a much larger process that has been developing beneath the surface for some time—underlying lesions and changes in the brain.

The ICEBERG cohort focuses on uncovering these hidden aspects through biomarkers, aiming to reveal the more subtle, fine details of PD progression. By identifying these early indicators, we can better understand the disease’s evolution, predict which cases will evolve faster, and ultimately detect Parkinson’s at its earliest stages.

Eye movements, in particular, have emerged as a promising biomarker, offering new possibilities for earlier detection and more precise tracking of the disease’s development.

Just like an iceberg, the biggest part of Parkinson’s remains hidden. This research aims to bring these unseen elements to light.

neuroClues’ Role in the Iceberg study

neuroClues® has been part of the ICEBERG study since April 2023, achieving the milestone of the first 50 patient recordings of oculomotor biomarkers.

2. Eye Movements to Detect Cognitive Impairement

As the global population ages, the prevalence of cognitive impairment is expected to rise, making early identification and intervention crucial. A recent reveiw by Leng et. al (2024) highlights the potential of advanced eye movement examinations as a valuable tool in the early detection and understanding of cognitive impairment.

Link to Publication

Advanced Eye Movements

Unlike low-level reflexive eye movements, advanced eye movements are voluntary and controlled by cortical and subcortical pathways, reflecting cognitive levels and functions. These include various types of saccades, such as shown here :

Clinical Features in Various Cognitive Disorders

Leng et al. (2024) presented a comprehensive table illustrating how neurological disorders associated with cognitive impairment show unique eye movement abnormalities, reinforcing the potential of this approach for identifying and distinguishing specific diseases.

Example : Parkinson’s Disease (PD) and Parkinson’s Disease Dementia (PDD)

Early PD is marked by prolonged anti-saccade latency and increased error rate.
PDD patients exhibit worse performance compared to PD patients in tasks such as anti-saccades, predictive saccades and pro-saccades.

Clinical Implications

Advanced eye movement examination offers a non-invasive, objective, and reproducible method, with potential as a biomarker for early screening and diagnosis of cognitive impairment. This approach may even outperform traditional neuropsychological scales in terms of screening efficacy and differentiation.

When integrated with neuropsychological assessments and other diagnostic tools, eye movement analysis holds promise for improving early detection and intervention, ultimately helping to delay disease progression.

So, where does this fit in the clinical journey of a patient?

What is the clinical question?

The physician’s concern is whether the patient is showing signs of cognitive impairment that could point toward the onset of dementia

Where is this question asked?

This question is typically posed during the initial consultation, where symptoms are first assessed, but it becomes especially important in follow-up appointments as the disease progresses.

Who asks the question?

It is the physician who raises this critical question, prompted by observed symptoms and cognitive changes.

At what point in the patient’s journey does this question arise?

During screening for at-risk populations—such as individuals with Parkinson’s disease after several years of disease progression.
When there’s clinical suspicion—either from the physician’s observations or from the family.

What is the impact on management?

If cognitive decline is detected, management can focus on:

Earlier detection, allowing for more timely and effective care, enabling tailored interventions based on the patient’s specific needs.
Objective measures, providing a way to monitor disease progression and assess the response to treatment, ensuring that therapies are as effective as possible.

3. Sneak Peak of Upcoming Newsletters

Over the coming months, we’ll be providing insights on how neuroClues^® can elevate your consultations, supported by compelling studies and research.

Here’s a preview of the upcoming newsletters:

March — Reflexive vs. Voluntary Saccades and their Neural Pathways
April — Exploring Anti-Saccades and Frontal Lobe Function
May — The Science Behind our Biomarker Computation

We’re going to be at these upcoming events, let’s meet!

Enjoyed this article?

Join our community to receive a monthly newsletter featuring insights on the relevance of eye tracking in the clinic and exclusive company updates

neuroClues secures CE certification for its eye-tracking technology set to enhance neurologic care - neuroClues

pierre — Tue, 07 Jan 2025 06:00:00 GMT

In summary

neuroClues achieves Medical Device Regulation (MDR) certification and is now allowed to issue the CE-mark on its Class IIa medical device designed to enhance neurologic care with eye movement biomarkers.

Its solution has been designed to bring to clinical practice a wealth of over 60 years of research.

The company is setting up strategic research partnerships and has ongoing discussions about its use in the French mega-cohort Constances.

The team positions itself for growth, with Bart Stulens appointed as Chief Commercial Officer, a former Medtronic executive bringing in over 25 years of experience.

It now plans to raise €10 million in Series A funding to support market expansion and build a European neurotech leader.

Paris, France – 7 January 2025 – neuroClues, a European MedTech company specializing in the diagnosis of neurodegenerative diseases, announced today it has received the MDR certificate for its groundbreaking eye-tracking device.

Innovation in the EU remains achievable with proper support and the right team. In just 4 years, the company developed a complete hardware, software, and cloud system, from incorporation to EU market access. By integrating European Medical Device Regulation (MDR) requirements from initial product design, the company achieved certification within five months, showcasing its efficient and compliant innovation process. This achievement was made possible through collaboration with their notified body, whose clinical and AI expertise streamlined the review process.

“This marks a major milestone for the millions of people affected by neurological disorders. neuroClues’ introduction to the EU market will improve diagnosis and care pathways for millions of EU patients, bringing objectivity to current clinical practice. This represents a significant value inflection point in our mission to improve neurodegenerative disease diagnosis,” said Antoine Pouppez, CEO and co-founder of neuroClues. “It demonstrates our team’s ability to deliver in a highly regulated environment with limited resources and proves that MedTech innovation remains possible in the EU.”

This achievement was made possible thanks to the support from the board (Olivier Legrain & Diane Lejeune), the investors (White Fund, Graph Ventures, InvestBW, LeanSquare & WING), the Walloon Region and the European Innovation Council (EIC) Fund.

neuroClues aims to address the pandemic of neurological disorders.

Neurological disorders are a silent pandemic affecting 1 in 3 people over their lifetime. Diagnosis is complex and primarily relies on clinical observation, leading to a long diagnostic odyssey with an approximately 30% misdiagnosis rate. This prolonged journey has a profound impact on patients’ health and severely affects their neurological state. Studies show that Parkinson’s patients have lost 50-70% of their dopaminergic neurons by the time of diagnosis.

neuroClues aims to transform years-long diagnostic wandering into rapid weeks-long processes in order to improve patient quality of life through proper care. The solution will initially target specialists like neurologists, movement disorder specialists, and neuro-ophthalmologists, before expanding to the 2.3 million physicians worldwide who currently assess brain health using the traditional “follow-my-finger” test.

neuroClues: enhancing neurologic care through eye movement biomarkers

The neuroClues device has built advanced eye-tracking technology using AI to analyze eye movements as biomarkers for neurological conditions. This portable, non-invasive and accurate solution complements existing diagnostic methods by extracting multiple biomarkers in 10 minutes while patients simply visually track a target on screen.

“Our unique device aims at empowering healthcare professionals with an easy-to-use tool for early detection of complex conditions like Parkinson’s disease and other neurodegenerative disorders,” said Pouppez.

neuroClues builds on 60+ years of eye movement research spanning 100,000+ publications from leading institutions worldwide. Gaining from its founding team’s expertise in neurology and with CE marking secured, neuroClues now bridges research insights and clinical needs, serving both daily practice and research applications.

Strategic Partnerships to foster translational neurologic research

neuroClues has established research partnerships with prominent studies across Europe and North America. In France, Professor Marie Vidailhet’s support allowed expanding subject enrollment using neuroClues within the Paris Brain Institute to dozens of participants per week. In the United States, studies are launching at two major institutions on hundreds of movement disorder patients.

Additional research collaborations are in the making, such as one with Professor Bas Bloem, Director at the Center of Expertise for Parkinson & Movement Disorders at Radboud University Nijmegen (Netherlands) who shared : “We are thrilled by the perspective of using neuroClues’ automated eye movements examination to help us better distinguish patients with atypical parkinsonian syndromes when the clinical signs are not evident yet.”

These collaborations demonstrate neuroClues’ dedication to driving evidence-based innovation and advancing the frontier of neurological research globally.

neuroClues advances collaboration with Constances Mega-Cohort for eye movement biomarkers

neuroClues is advancing discussions with the Constances cohort to integrate eye movement testing into their research for volunteers aged 55 and over. Constances, a renowned French epidemiological mega-cohort of 220,000 participants, offers a unique opportunity to collect data from 25,000 subjects. Supported by France 2030, this project would establish a comprehensive normative database of eye movement biomarkers. It aligns with neuroClues’ mission: leveraging eye movement analysis to revolutionize neurological care and enable earlier, more accurate diagnoses.

Expanding Borders and Broadening Neurological Applications

With its CE marking, neuroClues is prepared for deployment in hospitals and clinics across Europe, providing an innovative tool for neurologists and neuro-ophthalmologists. In Italy, Prof. Alessandra Rufa will lead efforts with neuroClues to develop normative databases for various neurological conditions, including Parkinson’s Disease, Alzheimer’s Disease, cerebellar syndromes, myasthenia, and myopathies. neuroClues goes beyond Parkinsonian syndromes, finding early adopters among dementia and sports medicine specialists, demonstrating its broad potential in diagnosing and managing neurological disorders across diverse fields.

Shaping up the organisation for commercial success: strategic addition to the executive leadership

neuroClues is delighted to announce the appointment of Bart Stulens as Chief Commercial Officer. With over 25 years of commercial and general management experience in the healthcare industry, including 16 years of senior leadership roles at Medtronic, Bart brings unparalleled expertise in implementing successful product launches and driving market expansion across multiple regions. His addition to the team underscores neuroClues commitment to enhancing its commercial capabilities and accelerating its growth trajectory.

Bart Stulens: “I am thrilled to join neuroClues at this pivotal moment and work alongside this talented team. neuroClues’ mission to “develop the stethoscope of the brain” and revolutionize neurologic care through early diagnosis aligns perfectly with my passion for driving innovation in healthcare. I look forward to contributing to the company’s growth and introduce groundbreaking solutions that will make a real difference in people’s lives.” 

Now planning a new Series A to build a European neurotech champion

Now that it has achieved market access, the company will be closing a Series A of 10 Million euros this half-year, 2/3 of which is already soft committed. With a proven track record of delivering on promises, the company aims to start growing the commercial team and bring its solution to the European market.

About neuroClues

neuroClues, formerly known as P3Lab, is a French Belgian startup founded in 2020. The company is developing a medical device based on eye-tracking to aid in the early diagnosis of neurological diseases. neuroClues is a partner of the Paris Brain Institute (France) and is incubated within the iPEPS-ICM, the Incubator of the Paris-Salpêtrière hospital. neuroClues has established a network of international collaborations in Europe and the United States. The company raised 4.7 million euros in 2021, received 2.5 million euros in grants from the European Innovation Council (EIC) Accelerator, and closed a 5 million euros Pre-Series A in 2024. neuroClues is now ambitioning to raise another 10 million euros, 2/3 of which is soft committed by existing investors, to develop this DeepTech innovation in the European and American markets. More information: https://neuroClues.com

For more information, please contact

Antoine POUPPEZ, CEO
antoine.pouppez@neuroclues.com
Louvain-la-Neuve
Belgium

They write about us: